Henoch-Schoenlein Purpura disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

HSP - MCID: HNC001 MIFTS: 61	Henoch-Schoenlein Purpura (HSP -) Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Immune diseases, Nephrological diseases, Rare diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Henoch-Schoenlein Purpura

MalaCards integrated aliases for Henoch-Schoenlein Purpura:

Name: Henoch-Schoenlein Purpura ¹¹ ¹⁴ ¹⁶ ⁷¹

Henoch-Schonlein Purpura ¹¹ ¹⁹ ⁵⁸ ⁵³

Iga Vasculitis ⁵⁸ ⁷⁵ ⁴³ ³³

Anaphylactoid Purpura ¹⁹ ⁵⁸ ³³

Rheumatoid Purpura ⁵⁸ ⁷⁵ ⁷¹

Allergic Purpura ¹¹ ³¹ ³³

Immunoglobulin a Vasculitis ¹⁹ ⁵⁸

Henoch-Schönlein Purpura ⁷⁵ ³³

Purpura Rheumatica ⁵⁸ ⁷¹

Vascular Purpura ¹⁹ ⁷⁵

Immunoglobulin-a Vasculitis ¹⁹

Purpura, Schonlein-Henoch ¹⁹

Purpura, Schönlein-Henoch ⁷⁵

[email protected] Purpura ¹¹

Henoch Schonlein Purpura ¹⁹

Schönlein-Henoch Purpura ³³

Henoch-Schnlein Purpura ¹¹

Henoch-Scholein Purpura ¹¹

Purpura, Autoimmune ¹¹

Autoimmune Purpura ¹¹

Hsp - ³³

Characteristics:

Prevelance:

Immunoglobulin a Vasculitis: 1-9/100000 (Norway) ⁵⁸

Age Of Onset:

Immunoglobulin a Vasculitis: Childhood ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Blood diseases Cardiovascular diseases Nephrological diseases Respiratory diseases Bone diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Coagulation defects, purpura and other haemorrhagic conditions

Purpura and other haemorrhagic conditions

Allergic purpura

ICD11: ³³

Diseases of the immune system

Nonorgan specific systemic autoimmune disorders

Vasculitis

Immune complex small vessel vasculitis

IgA vasculitis

Orphanet: ⁵⁸

Rare circulatory system diseases

Rare renal diseases

Rare respiratory diseases

Rare systemic and rhumatological diseases

External Ids:

Disease Ontology ¹¹ DOID:11123

ICD9CM ³⁴ 287.0

MeSH ⁴³ D011695

NCIt ⁴⁹ C34963

SNOMED-CT ⁶⁸ 191306005

ICD10 ³¹ D69.0

ICD10 via Orphanet ³² D69.0

UMLS via Orphanet ⁷² C0034152 C0086922

Orphanet ⁵⁸ ORPHA761

EFO ¹⁶ EFO_1000965

ICD11 ³³ 1629105375

UMLS ⁷¹ C0034152 C0086922 C0272295

Sources

Summaries for Henoch-Schoenlein Purpura

GARD: ¹⁹ Henoch-Schonlein purpura (HSP), also called immunoglobulin A vasculitis (IgAV), is a vascular disease that primarily affects small blood vessels. The disease is characterized by abnormal deposits of immunoglobulin A (an antibody) in the blood vessels, leading to their inflammation (vasculitis). The small vessels of the skin, joints, kidneys, and digestive organs are particularly involved. Signs and symptoms usually begin suddenly (and progress over days) and may include purple-colored spots on the skin (purpura); joint pain; and gastrointestinal problems such as abdominal pain, nausea, bloody stools, and rarely, severe complications requiring surgery. People with HSP may also develop glomerulonephritis (injury to the kidneys caused by inflammation) and poor kidney function, which may result in swelling of parts of the body or face (edema), and blood and protein in the urine (hematuria and proteinuria). Most cases of HSP occur in children and go away without causing serious or long-term health problems. Less commonly, the disease affects adults and may be more severe, leading to chronic kidney disease and kidney failure. The cause of HSP is not completely understood, but research indicates that genes (especially those involved in regulating the immune system) may play a key role in predisposing a person to HSP, as well as its severity. However, while genes may increase the risk of developing the disease (and in some cases more than one family member has HSP), the disease itself is not inherited. The diagnosis of HSP may be made based on symptoms, blood and urine tests, imaging studies, and/or a biopsy of the skin or kidney.

MalaCards based summary: Henoch-Schoenlein Purpura, also known as henoch-schonlein purpura, is related to purpura and acute kidney failure. An important gene associated with Henoch-Schoenlein Purpura is MEFV (MEFV Innate Immunity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and Complement cascade. The drugs Prednisone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and bone, and related phenotypes are nausea and vomiting and hematuria

Disease Ontology: ¹¹ A hypersensitivity vasculitis that is characterized by purpura (purplish plaques), arthralgia, gastrointestinal upset, and/or glomerulonephritis, and may be related to increased immune response following an infection.

Orphanet: ⁵⁸ A rare, small-vessel vasculitis characterized by skin purpura, arthritis, abdominal and/or renal involvement, IgA tissue deposits (arterioles, capillaries, and venules) and circulating IgA immune complexes.

Wikipedia ⁷⁵ Iga vasculitis: Henoch-Schönlein purpura (HSP), also known as IgA vasculitis, is a disease of the skin, mucous... more...

Vascular purpura: Purpura (/ˈpɜːrpjʊərə/) is a condition of red or purple discolored spots on the skin that do not blanch... more...

Sources

Related Diseases for Henoch-Schoenlein Purpura

Diseases related to Henoch-Schoenlein Purpura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1350)

#	Related Disease	Score	Top Affiliating Genes
1	purpura	31.8	TNF CRP CD79A C3
2	acute kidney failure	30.9	PRTN3 ALB ACE
3	duodenitis	30.9	TNF CRP ALB
4	microvascular complications of diabetes 5	30.8	VCAM1 ICAM1 ALB ACE
5	renal tuberculosis	30.8	CRP ALB
6	pulmonary hemosiderosis	30.8	PRTN3 MPO CRP
7	brucellosis	30.8	TNF MPO MEFV CRP
8	familial mediterranean fever	30.8	TNF MEFV CRP
9	intestinal obstruction	30.7	TNF CRP ALB
10	orchitis	30.7	TNF CRP CCR6
11	allergic cutaneous vasculitis	30.7	PRTN3 MPO
12	superior mesenteric artery syndrome	30.7	CRP ALB
13	testicular torsion	30.7	TNF MPO CRP
14	angina pectoris	30.7	TNF ICAM1 CRP ACE
15	exudative glomerulonephritis	30.7	CFHR2 C3
16	acute pancreatitis	30.6	TNF MPO ICAM1 CRP
17	central retinal artery occlusion	30.6	PRTN3 MPO CRP
18	mitral valve insufficiency	30.6	CRP ALB ACE
19	periodontitis	30.6	TNF MPO ICAM1 CRP
20	microscopic polyangiitis	30.6	PRTN3 MPO
21	drug allergy	30.6	CRP ALB ACE
22	compartment syndrome	30.6	TNF CRP ALB
23	kawasaki disease	30.6	VCAM1 TNF CRP
24	pharyngitis	30.6	TNF MEFV CRP CCR6
25	mononeuritis multiplex	30.5	TNF PRTN3 MPO CRP
26	pyuria	30.5	PRTN3 CRP C3 ALB
27	epidermolysis bullosa dystrophica, autosomal dominant	30.5	C3 ALB
28	retinal artery occlusion	30.5	ICAM1 CRP ACE
29	membranous nephropathy	30.5	CFHR2 CD79A ALB
30	macular retinal edema	30.5	TNF ICAM1 ALB ACE
31	food allergy	30.5	TNF RNASE3 ICOSLG CCR6
32	epidural abscess	30.5	CRP ALB
33	rheumatic heart disease	30.5	VCAM1 TNF ACE
34	dental caries	30.5	CRP CD79A ALB ACE
35	cervical adenitis	30.5	TNF MEFV CRP
36	autoimmune glomerulonephritis	30.5	ICOSLG CFHR2 CCR6
37	subacute bacterial endocarditis	30.5	PRTN3 MPO CRP ALB
38	tonsillitis	30.4	TNF MPO CD79A
39	osteomyelitis	30.4	TNF MEFV CRP
40	clostridium difficile colitis	30.4	CRP CCR6 ALB
41	hypertensive retinopathy	30.4	CRP ALB ACE
42	viral infectious disease	30.4	TNF ICOSLG ICAM1 CCR6
43	hidradenitis suppurativa	30.4	TNF MEFV CRP
44	immune-complex glomerulonephritis	30.4	PRTN3 ICOSLG CFHR2 C3 ALB
45	mesangial proliferative glomerulonephritis	30.4	CFHR2 CD79A C3 ALB
46	graves' disease	30.4	VCAM1 MPO ICOSLG ICAM1
47	ileus	30.4	TNF ICAM1 CRP
48	aortic valve insufficiency	30.4	CRP ALB ACE
49	diabetes mellitus, ketosis-prone	30.4	CRP ALB ACE
50	renal hypertension	30.4	CRP ALB ACE

Comorbidity relations with Henoch-Schoenlein Purpura via Phenotypic Disease Network (PDN):

Acute Cystitis	Deficiency Anemia
Familial Atrial Fibrillation	Heart Disease

Graphical network of the top 20 diseases related to Henoch-Schoenlein Purpura:

Sources

Symptoms & Phenotypes for Henoch-Schoenlein Purpura

Human phenotypes related to Henoch-Schoenlein Purpura:

⁵⁸ ³⁰ (show all 36)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	nausea and vomiting ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002017
2	hematuria ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000790
3	abdominal pain ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002027
4	arthralgia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002829
5	purpura ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000979
6	skin rash ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000988
7	bruising susceptibility ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000978
8	vasculitis ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002633
9	gastrointestinal infarctions ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0005244
10	pustule ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0200039
11	arthritis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001369
12	fever ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001945
13	skin ulcer ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0200042
14	anorexia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002039
15	myalgia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003326
16	migraine ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002076
17	erythema ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0010783
18	orchitis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100796
19	infectious encephalitis ³⁰	Frequent (33%)		HP:0002383
20	seizure ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001250
21	muscle weakness ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001324
22	optic atrophy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000648
23	proteinuria ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000093
24	renal insufficiency ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000083
25	hemiplegia/hemiparesis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0004374
26	glomerulopathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100820
27	gastrointestinal hemorrhage ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002239
28	macule ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012733
29	urticaria ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001025
30	episcleritis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100534
31	angioedema ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100665
32	restrictive ventilatory defect ³⁰	Occasional (7.5%)		HP:0002091
33	encephalitis ⁵⁸		Frequent (79-30%)
34	vascular skin abnormality ⁵⁸		Frequent (79-30%)
35	edema ⁵⁸		Occasional (29-5%)
36	restrictive deficit on pulmonary function testing ⁵⁸		Occasional (29-5%)

MGI Mouse Phenotypes related to Henoch-Schoenlein Purpura:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	9.93	ACE ALB C1GALT1 C1GALT1C1 C3 CCR6
2	immune system	MP:0005387	9.8	ACE ALB C1GALT1 C3 CCR6 CD79A
3	hematopoietic system	MP:0005397	9.4	ACE C1GALT1 C3 CCR6 CD79A ICAM1

Sources

Drugs & Therapeutics for Henoch-Schoenlein Purpura

Drugs for Henoch-Schoenlein Purpura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

4897

Antirheumatic Agents

Phase 4

Immunosuppressive Agents

Phase 4

Immunologic Factors

Phase 4

Anti-Infective Agents

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Antiemetics

Phase 4

glucocorticoids

Phase 4

Anti-Inflammatory Agents

Phase 4

Gastrointestinal Agents

Phase 4

Neuroprotective Agents

Phase 4

Methylprednisolone Acetate

Phase 4

584547

Protective Agents

Phase 4

Dermatologic Agents

Phase 4

Calcineurin Inhibitors

Phase 4

Cyclosporins

Phase 4

Antifungal Agents

Phase 4

Colchicine

Approved

Phase 3

64-86-8

2833 6167

Rituximab

Approved

Phase 3

174722-31-7

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Antibodies, Monoclonal

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Mycophenolic acid

Approved, Investigational

Phase 2

24280-93-1

446541

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

3003 5743

Benazepril

Approved, Investigational

Phase 2

86541-75-5

5362124

Leflunomide

Approved, Investigational

Phase 2

75706-12-6

3899

Dipyridamole

Approved

Phase 1, Phase 2

58-32-2

3108

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 1, Phase 2

9005-49-6

22833565 9812414 772

Reviparin

Approved, Investigational

Phase 1, Phase 2

9041-08-1

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Erlotinib

Approved, Investigational

Phase 1, Phase 2

183319-69-9, 183321-74-6

176870

Xylometazoline

Approved, Investigational

Phase 2

526-36-3

5709

Infliximab

Approved

Phase 2

170277-31-3

Azathioprine

Approved

Phase 2

446-86-6

2265

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Interventional clinical trials:

(show all 50)

#	Name	Status	NCT ID	Phase	Drugs
1	Off-label Use of Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis: Effectiveness and Safety	Completed	NCT03222687	Phase 4	tacrolimus;prednisone
2	HSP-glomerulonephritis Trial: MP vs CyA	Completed	NCT00425724	Phase 4	Methylprednisolone pulses plus prednisone versus Cyclosporine A
3	Evaluation of Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis	Recruiting	NCT04008316	Phase 3	Colchicine
4	Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or Relapsing IgA Vasculitis: A Prospective, Randomized, Controlled, Double-blind Study	Recruiting	NCT05329090	Phase 3	Rituximab Injection;placebo
5	The Research of Standard Diagnosis and Treatment for Severe Henoch-Schonlein Purpura in Children	Unknown status	NCT02540720	Phase 2	Dexamethasone;Gamma globulin
6	The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis With Mild Proteinuria in Children	Unknown status	NCT02532790	Phase 2	Prednisone;ACEI
7	The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis in Children	Unknown status	NCT02532777	Phase 2	Prednisone;Cyclophosphamide(CTX);Mycophenolate mofetil(MMF);Leflunomide(LEF);Angiotensin-converting enzyme inhibitor(ACEI);Methylprednisolone
8	Demonstrated Study on Children Henoch-Schönlein Purpura Nephritis With Multistep Treatment of Traditional Chinese Medicine Combined Disease and Syndrome Differentiation	Unknown status	NCT03591471	Phase 1, Phase 2	Glycosides Of Tripterygium Wilfordii Hook(GTW);Sulfotanshinone Sodium Injection;Chinese herbs based on syndrome differentiation;Prednisone Acetate Tablets;Benazepril Hydrochloride Tablets;Low Molecular Weight Heparin Calcium Injection;Dipyridamole Tab 25 MG;Chinese medicine placebo
9	Phase II Randomized, Double-Blinded Trial Of SGN-00101 (HSP-E7) For Treatment Of CIN II/III	Unknown status	NCT00060099	Phase 2
10	A Phase II Study of AUY922, a Novel HSP Inhibitor, in Patients With Advanced GIST Failed to or Intolerance of Imatinib and Sunitinib Therapy	Unknown status	NCT01389583	Phase 2	AUY922
11	A Phase 1-2 Ascending Dose Study To Assess The Pharmacodynamics, Pharmacokinetics, And Safety Of Hsp-130 In Subjects With Non-metastatic Breast Cancer Following Single-dose And Multiple-dose Administration By Subcutaneous Injection	Completed	NCT02650193	Phase 2	HSP-130
12	Phase II Evaluation Of SGN-00101 (HSP-E7) Fusion Protein In Women With Cervical Intraepithelial Neoplasia 3, CIN 3	Completed	NCT00054041	Phase 2
13	A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors	Completed	NCT01259089	Phase 1, Phase 2	erlotinib hydrochloride;Hsp90 inhibitor AUY922
14	Design and Validation of a Modular Physiotherapy Concept for the Treatment of Hereditary Spastic Spinal Paralysis (HSP) - a Randomized Study	Completed	NCT03961906	Phase 2
15	A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma	Completed	NCT01200238	Phase 2	STA-9090
16	Biologics in Refractory Vasculitis (BIOVAS): A Pragmatic, Randomised, Double-blind, Placebo-controlled, Modified-crossover Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis in Adults and Children	Recruiting	NCT05168475	Phase 2
17	A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases	Recruiting	NCT05003986	Phase 2	Sparsentan
18	A Randomized Multicenter Study for Isolated Skin Vasculitis	Recruiting	NCT02939573	Phase 2	Colchicine;Dapsone;Azathioprine
19	A Phase 1 Study Assessing The Pharmacodynamic And Pharmacokinetic Equivalence Of HSP-130 With US-approved Neulasta (Registered) And EU-approved Neulasta (Registered) Administered As A Single Subcutaneous Dose To Healthy Volunteers	Completed	NCT02629289	Phase 1	HSP-130;US-approved Neulasta;EU-approved Neulasta
20	Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors	Completed	NCT01246102	Phase 1	AT13387
21	Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura	Unknown status	NCT01610830
22	Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis	Unknown status	NCT02878018		Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula;angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant
23	A Single Center Randomized Controlled Clinical Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules	Unknown status	NCT04623866	Early Phase 1	Huaiqinhuang;valsartan
24	Study of Heat Shock Proteins as Prognostic Factor of Acute Renal Failure in Children (HSP-Study)	Unknown status	NCT00230412
25	CESAR (Randomized Therapeutic Study of Steroid vs. Steroid Plus Cyclosphosphamide for Severe Viscera Henoch-Schoenlein Purpura)	Completed	NCT00190229		Cyclophosphamide
26	Impact of Vasculitis on Employment and Income. An Online Survey of Participants in the VCRC Patient Contact Registry	Completed	NCT02476292
27	MMF Versus Intravenous CTX Pulses in the Treatment of Adult Severe Henoch-Schonlein Purpura Nephritis	Completed	NCT00301613		Mycophenolate mofetil
28	Reproductive Health in Men and Women With Vasculitis	Completed	NCT02176070
29	Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study)	Completed	NCT02190916
30	Educational Needs of Patients With Systemic Vasculitis- an International Survey	Completed	NCT02190929
31	The Journey of Patients With Vasculitis From First Symptom to Diagnosis	Completed	NCT03410290
32	The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura	Completed	NCT04387942		IL-2
33	Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura	Completed	NCT02317133
34	Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies.	Completed	NCT01715623
35	SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP)	Completed	NCT04256681
36	The Effect of Glutamine Infusion on the Inflammatory Response and HSP-70 in BMNCs During Human Experimental	Completed	NCT00780520
37	Descriptive Study About a Strategy of Micronutrient Management in Parturient and Layered Women With Proteochoc®, a Dietary Supplement Rich in Porphyra HSP®	Completed	NCT02967796
38	Study of RNA and Heat Shock Protein (HSP) Derived Biomarkers in Radiation-induced Fibrosis in Patients Treated for Breast Cancer.	Completed	NCT03000764
39	Studying Non-motor Symptoms in Patients With Hereditary Spastic Paraplegia (HSP) Compared to Healthy Controls	Completed	NCT03204773
40	Detection of Nontuberculous Mycobacterial co-Infection Using Duplex PCR for Mycobacterial Hsp 65 Gene and Its Clinical Significance in Patients With Smear Positive Pulmonary Tuberculosis	Completed	NCT00567151
41	Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS): Fundamental Observational in Vitro Study Using Samples From a Collection	Completed	NCT02873832
42	The Vasculitis Pregnancy Registry (V-PREG)	Recruiting	NCT02593565
43	VCRC Tissue Biorepository Collection Protocol	Recruiting	NCT02967068
44	Clinical Transcriptomics in Systemic Vasculitis (CUTIS)	Recruiting	NCT03004326
45	Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura	Recruiting	NCT03647852		Methylprednisolone;IVIG;other basic supportive treatment
46	Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia (HSP)	Recruiting	NCT04712812
47	Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors.	Recruiting	NCT04628806
48	Recherche d'un Marqueur Pronostique de l'Atteinte rénale du Purpura Rhumatoïde de l'Enfant. Validation de la méthode de détection Des IgA1 Avec Gradient de la Glycosylation Par spectrométrie de Masse	Active, not recruiting	NCT04655378
49	A Pilot Study of Shockwave Therapy for Lower Extremity Spasticity in Persons With Genetically-Confirmed HSP	Not yet recruiting	NCT05411627
50	Effect of Bacterial Colonization and Extracellular HSP-70 Expression in Sub-Glottic Secretions on Ventilator Free Days in Patients Receiving Mechanical Ventilation for Respiratory Failure or Airway Protection	Withdrawn	NCT02311296

Search NIH Clinical Center for Henoch-Schoenlein Purpura

Cochrane evidence based reviews: iga vasculitis

Sources

Genetic Tests for Henoch-Schoenlein Purpura

Sources

Anatomical Context for Henoch-Schoenlein Purpura

Organs/tissues related to Henoch-Schoenlein Purpura:

MalaCards : Skin, Kidney, Bone, T Cells, Breast, Skeletal Muscle, Lung

Sources

Publications for Henoch-Schoenlein Purpura

Articles related to Henoch-Schoenlein Purpura:

(show top 50) (show all 17858)

#	Title	Authors	PMID	Year
1	Tissue deposits of IgA-binding streptococcal M proteins in IgA nephropathy and Henoch-Schonlein purpura. ⁵³ ⁶²	Schmitt R...Karpman D	20056836	2010
2	Vasculitic IgA nephropathy: prognosis and outcome. ⁵³ ⁶²	Pankhurst T...Harper L	19342865	2009
3	Pathogenesis-related adhesion molecules in Henoch-Schonlein vasculitis. ⁵³ ⁶²	Gok F...Dagdeviren A	17701178	2008
4	Cardiac manifestations of Henoch-Schoenlein purpura: IgA mediated vasculitis or Rheumatic fever? ⁵³ ⁶²	Shin JI...Sul JH	17047991	2007
5	Efficacy of tonsillectomy plus methylprednisolone pulse therapy for a child with Henoch-Schoenlein purpura nephritis. ⁵³ ⁶²	Kawasaki Y...Hosoya M	17347555	2007
6	[Role of mast cells and eosinophil cationic protein in the pathogenesis of Henoch-Schonlein purpura nephritis]. ⁵³ ⁶²	Chen Y...Wang HW	16836844	2006
7	Circulating IgA from acute stage of childhood Henoch-Schönlein purpura can enhance endothelial interleukin (IL)-8 production through MEK/ERK signalling pathway. ⁵³ ⁶²	Yang YH...Chiang BL	16634798	2006
8	[Anti-mesangial cell autoantibodies and their target antigens in lupus nephritis]. ⁵³ ⁶²	Chen M...Zhao MH	14728876	2003
9	Enhanced expression of the CD71 mesangial IgA1 receptor in Berger disease and Henoch-Schönlein nephritis: association between CD71 expression and IgA deposits. ⁵³ ⁶²	Haddad E...Peuchmaur M	12538733	2003
10	A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. ⁵³ ⁶²	Ju T...Cummings RD	12464682	2002
11	Immunoglobulin A-associated lymphocytic vasculopathy: a clinicopathologic study of eight patients. ⁵³ ⁶²	Crowson AN...McNutt NS	12453297	2002
12	The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-alpha treatment in children with Henoch-Schönlein purpura. ⁵³ ⁶²	Yang YH...Chiang BL	12390327	2002
13	[Acute hemorrhagic edema of childhood and its differentiation from Schoenlein-Henoch purpura]. ⁵³ ⁶²	Vermeer MH...Smitt JH	11370431	2001
14	Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura. ⁵³ ⁶²	Yang YH...Chiang BL	11091287	2000
15	Tumor necrosis factor induced adhesion molecule serum concentrations in Henoch-Schönlein purpura and pediatric systemic lupus erythematosus. ⁵³ ⁶²	Gattorno M...Pistoia V	10990243	2000
16	Clinical, laboratory and molecular characteristics of children with Familial Mediterranean Fever-associated vasculitis. ⁵³ ⁶²	Tekin M...Cakar N	10709887	2000
17	[Anti-myeloperoxidase and anti-lactoferrin antibodies in patients with IgA nephropathy and Henoch-Schönlein purpura]. ⁵³ ⁶²	Nishiya K...Fujieda M	10097638	1999
18	Clinical features and natural history of IgA nephropathy. ⁵³ ⁶²	Rychlik I...Ritz E	10392260	1999
19	Immunogold labelling of cytokines in glomeruli in children with various renal diseases. ⁵³ ⁶²	Nakajima M...Yoshioka A	10516492	1999
20	Abnormal IgA glycosylation in Henoch-Schönlein purpura restricted to patients with clinical nephritis. ⁵³ ⁶²	Allen AC...Feehally J	9568852	1998
21	Is there IgA from gut mucosal origin in the serum of children with Henoch-Schönlein purpura? ⁵³ ⁶²	Moja P...Genin C	9557162	1998
22	Eosinophil cationic protein in Henoch-Schönlein purpura and in IgA nephropathy. ⁵³ ⁶²	Namgoong MK...Kim JS	9438647	1997
23	Properties of circulating IgA molecules in Henoch-Schönlein purpura nephritis with focus on neutrophil cytoplasmic antigen IgA binding (IgA-ANCA): new insight into a debated issue. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein purpura in adults and in children. ⁵³ ⁶²	Coppo R...Rollino C	9394310	1997
24	Plasma E-selectin and ICAM-1 in acute Henoch-Schönlein purpura. ⁵³ ⁶²	Willis FR...Beattie TJ	9279172	1997
25	Circulating soluble selectins in Kawasaki disease. ⁵³ ⁶²	Takeshita S...Yoshioka S	9182890	1997
26	[Diagnostic value of serum IGA-fibronectin aggregates to IGA nephropathy]. ⁵³ ⁶²	Wei L...Zhang Y	9812564	1997
27	Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation. ⁵³ ⁶²	Martin SJ...Esnault VL	9002541	1997
28	Pathological improvement of IgA nephropathy and Henoch-Schönlein purpura nephritis with urokinase therapy. ⁵³ ⁶²	Watanabe T...Hamasaki M	9002298	1996
29	Circulating adhesion molecules ICAM-1, E-selectin, and von Willebrand factor in Henoch-Schönlein purpura. ⁵³ ⁶²	Soylemezoglu O...Hasanoglu E	9014604	1996
30	Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management. ⁵³ ⁶²	Green RJ...Raffin TA	8915239	1996
31	IgA deposition in the skin of patients with alcoholic liver disease. ⁵³ ⁶²	Saklayen MG...Jalil K	8720981	1996
32	No pathogenic role of enhanced plasma IgA binding capacity to fibronectin and IgA-fibronectin aggregates in Henoch-Schönlein purpura. ⁵³ ⁶²	Davin JC...Mahieu P	8893175	1996
33	von Willebrand factor and factor XIII in children with Henoch-Schonlein purpura. ⁵³ ⁶²	De Mattia D...Schettini F	8580019	1995
34	Evolution of immunoglobulin A nephropathy into Henoch-Schönlein purpura in an adult patient. ⁵³ ⁶²	Araque A...Praga M	7847363	1995
35	Expression of MxA protein in inflammatory dermatoses. ⁵³ ⁶²	Fah J...Burg G	7822763	1995
36	Sequential occurrence of IgA nephropathy and Henoch-Schönlein purpura: support for common pathogenesis. ⁵³ ⁶²	Silverstein DM...Spitzer A	7696119	1994
37	A case report suggesting a common pathogenesis for IgA nephropathy and Henoch-Schönlein purpura. ⁵³ ⁶²	Kaneko K...Yabuta K	7696118	1994
38	IgA anticardiolipin antibodies associated with Henoch-Schönlein purpura. ⁵³ ⁶²	Burden AD...Tillman DM	7962736	1994
39	Lack of IgA antineutrophil cytoplasmic antibodies in Henoch-Schönlein purpura and IgA nephropathy. ⁵³ ⁶²	Sinico RA...D'Amico G	7923914	1994
40	[Studies on urinary protein components in renal disease in children, II--Comparison between children with orthostatic albuminuria and children with remission of glomerulonephritis]. ⁵³ ⁶²	Ohshima T	7815746	1994
41	Henoch-Schönlein purpura in a patient with diabetic nephropathy. ⁵³ ⁶²	Orfila C...Suc JM	8079978	1994
42	Henoch-Schoenlein purpura due to streptokinase. ⁵³ ⁶²	Zilliox AP...Slavin RG	8288725	1993
43	Serum anti-streptococcal IgA, IgG and IgM antibodies in IgA-associated diseases. ⁵³ ⁶²	Nakatsuka K	8503268	1993
44	Genetic study on HLA class II and class III region in the disease associated with IgA nephropathy. ⁵³ ⁶²	Abe J...Kobayashi N	8105396	1993
45	Autoimmunity to glomerular antigens in Henoch-Schoenlein nephritis. ⁵³ ⁶²	O'Donoghue DJ...Ballardie FW	1327645	1992
46	Increased levels of circulating intercellular adhesion molecule 1 in Kawasaki disease. ⁵³ ⁶²	Furukawa S...Yabuta K	1350908	1992
47	Accelerated expression of secreted alpha-chain gene in anaphylactoid purpura. ⁵³ ⁶²	Kondo N...Orii T	1400899	1992
48	[Studies on Hanganutziu-Deicher antibodies in renal diseases]. ⁵³ ⁶²	Seki K...Kikkawa Y	1316976	1992
49	Serum IgA-fibronectin aggregates in patients with IgA nephropathy and Henoch-Schönlein purpura: diagnostic value and pathogenic implications. The Glomerular Disease Collaborative Network. ⁵³ ⁶²	Jennette JC...Falk RJ	1928066	1991
50	Renal expression of intercellular adhesion molecule-1 in different forms of glomerulonephritis. ⁵³ ⁶²	Lhotta K...Konig P	1682080	1991

Sources

Genes for Henoch-Schoenlein Purpura

Genes related to Henoch-Schoenlein Purpura (0 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MEFV	MEFV Innate Immunity Regulator, Pyrin	Protein Coding	13.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10709887
2	CD79A	CD79a Molecule	Protein Coding	12.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9568852 9557162 1928066 (more) 9002298 7847363 1400899 7923914 9812564 8503268 11091287 9394310 7696118 8105396 7696119 1327645 7962736 8288725 7815746 12390327 19342865 8079978 17347555 17047991 10516492 1682080 10392260 9002541 1802552 20056836 16634798 12538733 8720981 8580019 12464682 11370431 8893175 12453297 14728876 1316976 8915239
3	MPO	Myeloperoxidase	Protein Coding	11.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10097638
4	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	9.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9014604 17701178 9279172 (more) 1350908 10990243
5	CFHR2	Complement Factor H Related 2	Protein Coding	8.08	DISEASES inferred ¹⁴ ¹⁴
6	VCAM1	Vascular Cell Adhesion Molecule 1	Protein Coding	7.74	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9182890 17701178 10990243
7	PRTN3	Proteinase 3	Protein Coding	7.02	DISEASES inferred ¹⁴
8	RNASE3	Ribonuclease A Family Member 3	Protein Coding	6.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9438647 16836844
9	MIR98	MicroRNA 98	RNA Gene	6.91	DISEASES inferred ¹⁴ ¹⁴
10	CRP	C-Reactive Protein	Protein Coding	6.74	DISEASES inferred ¹⁴
11	MEST	Mesoderm Specific Transcript	Protein Coding	6.7	DISEASES inferred ¹⁴
12	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	6.58	DISEASES inferred ¹⁴ ¹⁴
13	ALB	Albumin	Protein Coding	6.54	DISEASES inferred ¹⁴
14	C3	Complement C3	Protein Coding	6.49	DISEASES inferred ¹⁴
15	FCAR	Fc Alpha Receptor	Protein Coding	6.49	DISEASES inferred ¹⁴
16	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	6.17	DISEASES inferred ¹⁴ ¹⁴
17	ACE	Angiotensin I Converting Enzyme	Protein Coding	6.12	DISEASES inferred ¹⁴
18	C1GALT1C1	C1GALT1 Specific Chaperone 1	Protein Coding	5.96	DISEASES inferred ¹⁴
19	TNF	Tumor Necrosis Factor	Protein Coding	5.92	DISEASES inferred ¹⁴
20	C1GALT1	Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1	Protein Coding	5.92	DISEASES inferred ¹⁴
21	IL6	Interleukin 6	Protein Coding	5.84	DISEASES inferred ¹⁴
22	SERPINA3	Serpin Family A Member 3	Protein Coding	5.82	DISEASES inferred ¹⁴ ¹⁴
23	CD4	CD4 Molecule	Protein Coding	5.73	DISEASES inferred ¹⁴

Sources

Variations for Henoch-Schoenlein Purpura

Copy number variations for Henoch-Schoenlein Purpura from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	210503	6	30400000	36600000	Copy number	C4B	Henoch-schoenlein purpura

Sources

Expression for Henoch-Schoenlein Purpura

Search GEO for disease gene expression data for Henoch-Schoenlein Purpura.

Sources

Pathways for Henoch-Schoenlein Purpura

Pathways related to Henoch-Schoenlein Purpura according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.55	VCAM1 TNF RNASE3 PRTN3 MPO MEFV
2	Complement cascade ⁶⁶ Show member pathways Activation of C3 and C5 ⁶⁶ Classical Complement Pathway ⁶⁴ Complement Pathway ⁶⁴ Complement system ⁷⁴ Complement system in neuronal development and plasticity ⁷⁴ Lectin Induced Complement Pathway ⁶⁴ Regulation of Complement cascade ⁶⁶	12.28	ICAM1 CRP CFHR2 C3 ALB
3	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.41	VCAM1 TNF ICAM1
4	miRNAs involvement in the immune response in sepsis ⁷⁴	11.37	VCAM1 TNF ICAM1
5	Netrin-UNC5B signaling pathway ⁷⁴	11.26	VCAM1 TNF ICAM1
6	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.2	TNF ICOSLG CRP CD79A C3
7	Beta2 integrin cell surface interactions ⁶¹	10.9	VCAM1 ICAM1 C3
8	LDL Oxidation in Atherogenesis ⁶⁴	10.13	VCAM1 TNF MPO ICAM1

Sources

GO Terms for Henoch-Schoenlein Purpura

Cellular components related to Henoch-Schoenlein Purpura according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	external side of plasma membrane	GO:0009897	9.8	VCAM1 TNF ICOSLG ICAM1 CD79A CCR6
2	azurophil granule lumen	GO:0035578	9.76	RNASE3 PRTN3 MPO C3
3	extracellular space	GO:0005615	9.68	ACE ALB C3 CFHR2 CRP ICAM1

Biological processes related to Henoch-Schoenlein Purpura according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane to membrane docking	GO:0022614	9.56	VCAM1 ICAM1
2	O-glycan processing, core 1	GO:0016267	9.46	C1GALT1 C1GALT1C1
3	response to gold nanoparticle	GO:1990268	9.26	TNF MPO
4	cellular response to amyloid-beta	GO:1904646	9.17	VCAM1 TNF MIR98 ICAM1